What Is Prostate Cancer?

Prostate cancer is a malignancy that develops in the prostate gland, a small walnut-shaped organ located just below the bladder in men. It is one of the most common cancers among men worldwide. The prostate produces seminal fluid that nourishes and transports sperm, and its proximity to the urethra, bladder, and nerves controlling erections means that both the disease and its treatments can significantly affect urinary and sexual function.

Most prostate cancers are adenocarcinomas, meaning they arise from the glandular cells that line the prostate ducts. While some prostate cancers grow slowly and may never cause symptoms during a man's lifetime, others are aggressive and can spread (metastasize) to bones, lymph nodes, and other organs. Understanding the spectrum of prostate cancer, from low-risk to high-risk disease, is essential for making informed decisions about prostate cancer screening, prostate cancer diagnosis, and prostate cancer treatment.

According to the American Cancer Society, approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Despite being the second-leading cause of cancer death in American men, the prostate cancer survival rate is encouraging: when detected early, the five-year relative survival rate exceeds 99 percent.

Key Takeaways

1. High prevalence: Prostate cancer is the most commonly diagnosed non-skin cancer in men, with over 288,000 new cases estimated annually in the United States.
2. Age matters: Risk increases sharply after age 50, and roughly 60 percent of cases are diagnosed in men over 65.
3. Family history counts: Having a first-degree relative with prostate cancer more than doubles your risk.
4. Race is a major factor: Black men face a 70 percent higher incidence rate and more than double the mortality rate compared to white men.
5. PSA screening saves lives but has trade-offs: The PSA test can detect prostate cancer early, but may also lead to overdiagnosis and unnecessary treatment.
6. Not all prostate cancers need immediate treatment: Low-risk cancers may be safely monitored with active surveillance rather than surgery or radiation.
7. Treatment side effects are real: Erectile dysfunction, urinary incontinence, and bowel changes are common concerns that deserve open conversation with your care team.
8. Sexual health recovery is possible: Many men regain erectile function over time with rehabilitation strategies, medications, and support.
9. Survival rates are high: The overall five-year survival rate for prostate cancer is approximately 97 percent across all stages.
10. Lifestyle choices matter: Diet, exercise, and maintaining a healthy weight may reduce prostate cancer risk and improve outcomes after diagnosis.

Prostate Anatomy and Function

The prostate gland sits beneath the bladder and in front of the rectum. The urethra, which carries urine from the bladder and semen from the reproductive system, passes directly through the center of the prostate. This anatomical position explains why prostate conditions, whether benign enlargement or cancer, frequently cause urinary symptoms.

The prostate is divided into several zones:

• Peripheral zone: The outermost region where approximately 70 to 80 percent of prostate cancers originate. This zone is accessible during a digital rectal exam (DRE).
• Transition zone: Surrounds the urethra and is the area where benign prostatic hyperplasia (BPH) most commonly develops.
• Central zone: Surrounds the ejaculatory ducts. Cancers here are less common but tend to be more aggressive.
• Anterior fibromuscular stroma: A non-glandular area composed mainly of muscle and fibrous tissue.

The prostate produces prostatic fluid, which makes up roughly 20 to 30 percent of semen volume. This fluid contains enzymes like prostate-specific antigen (PSA), citric acid, and zinc, all of which support sperm viability and motility. The prostate also contains smooth muscle fibers that help propel semen during ejaculation.

Understanding prostate anatomy is critical because the nerves that control erections (the neurovascular bundles) run along the outside of the prostate. Surgical removal of the prostate or radiation therapy can damage these nerves, directly affecting sexual function, which is why nerve-sparing techniques are so important in modern treatment.

Prostate Cancer Risk Factors

While the exact cause of prostate cancer remains unknown, several well-established prostate cancer risk factors influence a man's likelihood of developing the disease:

Age

Age is the single strongest risk factor for prostate cancer. The disease is rare before age 40, but incidence rises steeply with each subsequent decade. Approximately 60 percent of all prostate cancer diagnoses occur in men aged 65 and older, and the average age at diagnosis is 66.

Race and Ethnicity

Significant racial disparities exist in prostate cancer incidence and outcomes. Black men in the United States are approximately 70 percent more likely to develop prostate cancer than white men and are more than twice as likely to die from the disease. Contributing factors may include genetic susceptibility, differences in access to healthcare, socioeconomic factors, and potential biological differences in tumor behavior. Asian and Hispanic men generally have lower incidence rates.

Family History and Genetics

A strong family history is a significant risk factor. Men with a father or brother diagnosed with prostate cancer have roughly double the risk. The risk is even higher if multiple first-degree relatives were affected or if relatives were diagnosed before age 55. Inherited mutations in genes such as BRCA1, BRCA2, HOXB13, and Lynch syndrome genes (mismatch repair genes) are associated with increased prostate cancer risk. Men with BRCA2 mutations in particular face a substantially elevated risk of aggressive prostate cancer.

Diet and Obesity

Diets high in red meat, processed meats, and high-fat dairy products have been associated with a modestly increased prostate cancer risk in some studies, though findings are not entirely consistent. Obesity is more clearly linked to aggressive prostate cancer and poorer outcomes after treatment. Men with a body mass index (BMI) above 30 have a higher risk of being diagnosed with advanced-stage disease.

Geographic and Environmental Factors

Prostate cancer rates are highest in North America, Europe, Australia, and the Caribbean, and lowest in Asia and Africa. Migration studies show that men who move from low-risk to high-risk countries see their risk increase over time, suggesting that environmental and lifestyle factors play a role alongside genetics. Exposure to certain chemicals, including Agent Orange and cadmium, has also been linked to increased risk.

Other Factors Under Investigation

• Inflammation: Chronic prostatitis and prostatic inflammation may contribute to cancer development.
• Hormones: Higher levels of testosterone and insulin-like growth factor-1 (IGF-1) have been studied as potential risk modifiers.
• Vasectomy: Some studies suggest a very small increased risk, though evidence remains inconclusive.
• Sexually transmitted infections: Certain infections may contribute to chronic inflammation and slightly elevated risk.

Prostate Cancer Symptoms

One of the challenges with prostate cancer is that early-stage disease often produces no noticeable prostate cancer symptoms. Most cancers detected through screening are asymptomatic. When symptoms do appear, they frequently overlap with those of benign conditions like BPH or prostatitis.

Early and Localized Symptoms

• Frequent urination, especially at night (nocturia)
• Difficulty starting or stopping urination
• Weak or interrupted urine stream
• Burning or pain during urination
• Blood in urine (hematuria) or semen (hematospermia)
• Painful ejaculation
• Difficulty achieving or maintaining an erection

Advanced or Metastatic Symptoms

When prostate cancer spreads beyond the gland, additional symptoms may develop:

• Deep, persistent bone pain, particularly in the hips, spine, ribs, or pelvis
• Unexplained weight loss and fatigue
• Swelling in the legs or pelvic area (due to lymph node involvement)
• Numbness or weakness in the legs or feet (spinal cord compression)
• Loss of bladder or bowel control

It is important to understand that these symptoms are not unique to prostate cancer. However, any persistent urinary changes or unexplained bone pain in a man over 50 should prompt a medical evaluation. Early detection through prostate cancer screening remains the most reliable way to catch the disease before symptoms develop.

Screening and the PSA Test

Prostate cancer screening typically involves two components: the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE). Screening remains one of the most debated topics in oncology because of the balance between early detection benefits and the risks of overdiagnosis.

The PSA Test Explained

The PSA test measures the level of prostate-specific antigen, a protein produced by both normal and cancerous prostate cells, in the blood. A PSA level above 4.0 ng/mL has traditionally been considered elevated, though there is no single threshold that definitively indicates cancer. Important considerations include:

• PSA velocity: How quickly PSA levels rise over time may be more informative than a single reading.
• PSA density: PSA level relative to prostate volume can help distinguish cancer from BPH.
• Free vs. total PSA: A lower percentage of free PSA may suggest a higher likelihood of cancer.
• Age-adjusted ranges: PSA levels naturally rise with age, so what is considered "normal" varies by age group.

Screening Guidelines

Major medical organizations have varying recommendations, but most agree on shared decision-making:

• American Cancer Society (ACS): Informed discussion starting at age 50 for average-risk men, age 45 for high-risk men (Black men and those with a first-degree relative diagnosed before 65), and age 40 for men at very high risk (multiple first-degree relatives with early diagnoses).
• U.S. Preventive Services Task Force (USPSTF): Recommends individualized decision-making for men ages 55 to 69 and recommends against screening for men 70 and older.
• American Urological Association (AUA): Shared decision-making for men ages 55 to 69, with earlier discussion for high-risk groups.

Beyond PSA: Advanced Screening and Diagnostic Tools

When PSA results are ambiguous or elevated, additional tools help refine prostate cancer diagnosis:

• Multiparametric MRI (mpMRI): Non-invasive imaging that can identify suspicious lesions and guide targeted biopsy.
• Biomarker tests: Tests like the 4Kscore, Prostate Health Index (phi), SelectMDx, ExoDx Prostate (EPI), and IsoPSA help assess cancer probability and reduce unnecessary biopsies.
• MRI-fusion biopsy: Combines MRI imaging with real-time ultrasound guidance for more accurate tissue sampling.
• Genomic tests: After biopsy, tests like Oncotype DX Prostate, Prolaris, and Decipher can help predict cancer aggressiveness and guide treatment decisions.

Prostate Cancer Stages

Accurate staging is essential for determining prognosis and selecting the most appropriate prostate cancer treatment. The most widely used system is the American Joint Committee on Cancer (AJCC) TNM staging system, which evaluates the tumor (T), lymph nodes (N), and metastasis (M), along with PSA level and Gleason score (Grade Group).

Gleason Score and Grade Groups

The Gleason scoring system grades prostate cancer based on how cancer cells look under a microscope. A pathologist assigns two grades (each from 1 to 5) to the two most prevalent patterns in the biopsy, and the sum becomes the Gleason score (ranging from 6 to 10). More recently, the Grade Group system has been adopted to simplify interpretation:

• Grade Group 1 (Gleason 6): Low-grade, slow-growing cancer
• Grade Group 2 (Gleason 3+4=7): Intermediate, mostly well-formed glands
• Grade Group 3 (Gleason 4+3=7): Intermediate, mostly poorly formed glands
• Grade Group 4 (Gleason 8): High-grade cancer
• Grade Group 5 (Gleason 9-10): Highest-grade cancer

Prostate Cancer Staging Table

The staging of prostate cancer directly shapes treatment recommendations. Men with Stage I or low-volume Stage II disease may be candidates for active surveillance, while Stage III and IV cancers typically require more aggressive multimodal therapy.

Prostate Cancer Treatment Options

The range of prostate cancer treatment options has expanded significantly, allowing for increasingly personalized care. Treatment selection depends on the cancer stage, grade, PSA level, patient age, overall health, personal preferences, and tolerance for potential side effects.

Active Surveillance

Active surveillance is a strategy of closely monitoring low-risk prostate cancer with regular PSA tests, DREs, imaging (often MRI), and periodic biopsies, while deferring immediate treatment. It is appropriate for men with Grade Group 1 (Gleason 6) cancer and select cases of favorable Grade Group 2 disease. The goal is to avoid or delay the side effects of treatment while intervening promptly if the cancer shows signs of progression. Studies show that at 10 years, active surveillance has outcomes comparable to immediate treatment for low-risk disease.

Surgery (Radical Prostatectomy)

Radical prostatectomy involves the complete surgical removal of the prostate gland, seminal vesicles, and sometimes nearby lymph nodes. Approaches include open, laparoscopic, and robotic-assisted surgery (the most common in the United States). Nerve-sparing techniques aim to preserve the neurovascular bundles to maintain erectile function. Potential side effects include urinary incontinence (usually improving over 6 to 12 months) and erectile dysfunction.

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells. The two main approaches are:

• External beam radiation therapy (EBRT): Precisely targeted radiation delivered from outside the body over several weeks. Modern techniques include intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiation therapy (SBRT), and proton therapy.
• Brachytherapy: Radioactive seeds or sources are placed directly into or near the prostate. Can be low-dose rate (permanent seed implants) or high-dose rate (temporary).

Radiation therapy may be combined with androgen deprivation therapy (ADT) for intermediate- and high-risk cancers. Side effects can include urinary irritation, bowel changes, fatigue, and erectile dysfunction that may develop gradually over months to years.

Hormone Therapy (Androgen Deprivation Therapy)

Prostate cancer cells rely on androgens (primarily testosterone) to grow. ADT reduces androgen levels or blocks their action. It is used as a primary treatment for advanced cancer, in combination with radiation for intermediate/high-risk localized disease, and for recurrent cancer. Types include LHRH agonists, LHRH antagonists, anti-androgens, and newer agents like abiraterone and enzalutamide. Side effects include hot flashes, loss of libido, erectile dysfunction, weight gain, bone loss, fatigue, mood changes, and metabolic changes.

Chemotherapy

Chemotherapy (commonly docetaxel or cabazitaxel) is used primarily for metastatic castration-resistant prostate cancer (mCRPC) or in combination with ADT for high-volume metastatic hormone-sensitive disease. It works by killing rapidly dividing cells throughout the body.

Focal Therapy

Focal therapy treats only the cancerous area of the prostate while preserving the rest of the gland. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, laser ablation, and irreversible electroporation (NanoKnife). These approaches aim to reduce side effects but are still considered investigational for many cases and are best suited for selected patients with well-defined, unifocal disease.

Treatment Comparison Table

Emerging Treatments

• Immunotherapy: Sipuleucel-T (Provenge) is an FDA-approved vaccine for certain men with metastatic CRPC. Checkpoint inhibitors (like pembrolizumab) may benefit men whose tumors have specific biomarkers such as MSI-high or dMMR.
• PARP inhibitors: Olaparib and rucaparib are approved for men with metastatic CRPC who carry specific DNA repair gene mutations (e.g., BRCA1/2).
• Radioligand therapy: Lutetium-177-PSMA-617 (Pluvicto) targets PSMA-expressing cancer cells and has shown improved survival in advanced disease.
• Combination regimens: Ongoing clinical trials are exploring novel combinations of hormonal agents, targeted therapies, and immunotherapies.

Prostate Cancer and Sexual Health

The relationship between prostate cancer and sexual health is one of the most important quality-of-life considerations for patients and their partners. Because the prostate is anatomically intertwined with the nerves, blood vessels, and muscles involved in erections and ejaculation, virtually all prostate cancer treatments carry some risk of sexual side effects.

How Treatments Affect Sexual Function

Surgery (radical prostatectomy): Even with nerve-sparing techniques, most men experience some degree of erectile dysfunction immediately after surgery. Recovery of erectile function typically occurs gradually over 12 to 24 months, and the degree of recovery depends on age, baseline function, cancer extent, and whether nerves could be preserved. After prostatectomy, men will no longer ejaculate semen (dry orgasm), though the sensation of orgasm is usually preserved.

Radiation therapy: Erectile dysfunction from radiation tends to develop gradually over months to years rather than immediately. Approximately 30 to 50 percent of men experience significant erectile difficulties within 2 to 5 years of treatment. Radiation may also cause changes in ejaculate volume, orgasm intensity, and occasionally mild discomfort.

Hormone therapy: ADT dramatically reduces testosterone, leading to loss of libido, erectile dysfunction, reduced penile size, loss of body hair, breast tenderness or enlargement, and emotional changes. These effects are nearly universal during active treatment and may not fully reverse after stopping therapy.

Erectile Rehabilitation

Penile rehabilitation is the practice of using interventions early after treatment to promote blood flow and nerve recovery. Strategies include:

• PDE5 inhibitors: Medications like sildenafil (Viagra), tadalafil (Cialis), and vardenafil may be prescribed on a regular schedule (often low-dose daily tadalafil) to promote blood flow.
• Vacuum erection devices (VED): Mechanical pumps that draw blood into the penis and maintain an erection with a constriction ring.
• Penile injections: Intracavernosal injections of alprostadil or combination medications (trimix) can produce erections regardless of nerve status.
• Intraurethral suppositories: MUSE (medicated urethral system for erection) delivers alprostadil directly into the urethra.
• Penile implants: Surgically placed devices (inflatable or semi-rigid) offer a permanent solution when other methods are insufficient. Patient satisfaction rates exceed 90 percent.

Intimacy Beyond Erections

Sexual health after prostate cancer is about far more than erectile function. Open communication with a partner, emotional intimacy, counseling, and exploring new forms of physical closeness are all essential components of recovery. Many cancer centers now offer sexual health programs staffed by urologists, psychologists, and sex therapists who specialize in oncology.

Men should feel empowered to discuss sexual concerns with their healthcare team before, during, and after treatment. Addressing these issues proactively leads to better outcomes and greater satisfaction.

Survivorship and Quality of Life

With a prostate cancer survival rate that exceeds 97 percent at five years across all stages combined, there are more than 3.3 million prostate cancer survivors in the United States. Survivorship care focuses on managing treatment side effects, monitoring for recurrence, and optimizing long-term health.

Post-Treatment Monitoring

After definitive treatment, regular PSA monitoring is the cornerstone of follow-up. After surgery, PSA should drop to undetectable levels; a rising PSA may indicate biochemical recurrence. After radiation, PSA declines gradually, and recurrence is typically defined as a rise of 2.0 ng/mL or more above the lowest post-treatment value (nadir). Follow-up schedules generally include PSA testing every 3 to 6 months for the first 5 years and annually thereafter.

Managing Long-Term Side Effects

• Urinary incontinence: Pelvic floor exercises (Kegels), biofeedback, behavioral therapies, and if needed, surgical slings or artificial urinary sphincters.
• Erectile dysfunction: The rehabilitation approaches described above, applied with patience and persistence.
• Bowel issues: Dietary modifications, medications, and occasionally interventional procedures for radiation-related bowel changes.
• Hormonal side effects: Weight management, bone density monitoring, cardiovascular risk management, resistance exercise, and mental health support for men on ADT.
• Emotional well-being: Anxiety about recurrence, depression, relationship strain, and identity concerns are common. Professional counseling, support groups, and peer networks can be transformative.

Exercise and Rehabilitation

Strong evidence supports regular physical activity for prostate cancer survivors. Exercise can improve fatigue, cardiovascular health, bone density, body composition, mood, and potentially survival. Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week plus two or more sessions of resistance training. Supervised exercise programs designed for cancer survivors have shown particular benefit.

Prostate Cancer Prevention

While there is no guaranteed way to prevent prostate cancer, evidence supports several strategies that may reduce risk or detect the disease at its most treatable stage:

Dietary Approaches

• Plant-rich diet: Emphasize fruits, vegetables, whole grains, and legumes. Lycopene (found in tomatoes), cruciferous vegetables (broccoli, cauliflower), and soy products have shown potential protective effects in some studies.
• Healthy fats: Replace saturated fats with omega-3 fatty acids from fish, nuts, and olive oil.
• Limit red and processed meat: High consumption has been linked to modestly increased risk in some studies.
• Moderate dairy intake: Very high calcium intake (over 2,000 mg/day) may be associated with increased risk.

Lifestyle Factors

• Maintain a healthy weight: Obesity is associated with more aggressive prostate cancer and worse outcomes.
• Exercise regularly: Physical activity is associated with a reduced risk of aggressive prostate cancer and improved overall mortality.
• Avoid smoking: While smoking may not cause prostate cancer directly, smokers diagnosed with prostate cancer have worse outcomes and higher mortality.
• Limit alcohol: Heavy alcohol consumption may increase risk; moderation is advisable.

Chemoprevention

The PCPT and REDUCE clinical trials demonstrated that 5-alpha reductase inhibitors (finasteride and dutasteride) can reduce overall prostate cancer risk by approximately 23 to 25 percent. However, they may slightly increase the detection of high-grade cancers, and they are not currently recommended as general preventive agents by most guidelines. Discuss the potential benefits and risks with a healthcare provider if you are at elevated risk.

Screening as Prevention

While screening does not prevent prostate cancer from developing, it enables early detection when the disease is most curable. Men should engage in shared decision-making with their physicians about the benefits and risks of PSA-based screening, particularly those in high-risk groups.

Frequently Asked Questions

What is the most common first sign of prostate cancer?

Most prostate cancers, especially early-stage disease, produce no symptoms at all. When symptoms do develop, the most common early signs are urinary changes such as frequent urination (particularly at night), weak stream, or difficulty starting urination. However, these symptoms overlap significantly with benign prostatic hyperplasia (BPH), which is far more common. An elevated PSA test result is often the earliest indicator of possible prostate cancer.

At what age should I start prostate cancer screening?

Most guidelines recommend that men at average risk discuss prostate cancer screening with their doctor starting at age 50. Men at higher risk, including Black men and those with a first-degree relative diagnosed with prostate cancer before age 65, should begin the conversation at age 45. Men with multiple first-degree relatives with early-onset prostate cancer should consider discussion at age 40.

What PSA level indicates prostate cancer?

There is no single PSA level that definitively indicates prostate cancer. Traditionally, a PSA above 4.0 ng/mL has been used as a threshold for further evaluation, but cancer can be present at lower levels and many men with elevated PSA do not have cancer. PSA velocity, PSA density, free-to-total PSA ratio, and additional biomarkers help refine risk assessment. Your doctor will interpret PSA results in the context of your age, prostate size, family history, and other factors.

Is prostate cancer hereditary?

Prostate cancer has a significant hereditary component. Approximately 5 to 10 percent of cases are thought to be driven primarily by inherited genetic factors. Having a father or brother with prostate cancer roughly doubles your risk. Specific gene mutations, including BRCA2, BRCA1, HOXB13, and Lynch syndrome genes, carry elevated risk. Genetic counseling and testing may be recommended for men with a strong family history.

What is active surveillance and is it safe?

Active surveillance is a management strategy for low-risk prostate cancer that involves regular monitoring with PSA tests, digital rectal exams, MRI imaging, and periodic prostate biopsies, while holding off on treatment unless the cancer shows signs of progression. Multiple long-term studies have confirmed its safety for appropriately selected patients, showing that at 10 to 15 years, outcomes are comparable to immediate surgery or radiation for low-risk disease, while avoiding treatment side effects.

What are the side effects of prostate cancer surgery?

The two most significant side effects of radical prostatectomy are erectile dysfunction and urinary incontinence. Most men experience some degree of both immediately after surgery. Urinary control typically improves over 3 to 12 months, with 80 to 95 percent of men achieving satisfactory continence. Erectile function recovery depends on nerve preservation, age, and pre-surgery function, with 40 to 70 percent of men recovering erections sufficient for intercourse within 2 years. Other risks include surgical complications, bladder neck contracture, and changes in orgasm (dry ejaculation).

How does prostate cancer affect sexual function?

Prostate cancer and its treatments can affect sexual function in multiple ways, including erectile dysfunction, changes in libido, alterations in orgasm quality, loss of ejaculate (after surgery), and emotional impacts on intimacy. The degree of impact depends on the treatment type, extent of nerve preservation, baseline sexual function, age, and psychosocial factors. Erectile rehabilitation strategies, medications, and professional support can help most men maintain or recover sexual intimacy.

Can prostate cancer be cured?

When detected at an early stage (localized or regional), prostate cancer is highly curable. The five-year relative survival rate for localized and regional prostate cancer is nearly 100 percent. Even men with biochemical recurrence after initial treatment often have many additional treatment options. Advanced metastatic prostate cancer is generally not considered curable, but it can often be controlled for many years with systemic therapies, and survival continues to improve with newer treatments.

What is the Gleason score?

The Gleason score is a grading system that evaluates how prostate cancer cells look under a microscope. A pathologist assigns grades from 1 to 5 to the two most prominent patterns in the biopsy tissue, and these are added together to produce the Gleason score (most commonly 6 to 10). A Gleason 6 (Grade Group 1) indicates low-grade cancer, 7 indicates intermediate-grade, and 8 to 10 indicates high-grade cancer. The Gleason score is one of the most important factors in determining prognosis and treatment.

How is prostate cancer different from BPH?

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate that is extremely common as men age. BPH and prostate cancer can cause similar urinary symptoms, but they are different conditions. BPH does not turn into cancer, though both can coexist. BPH typically affects the transition zone (inner prostate), while most cancers arise in the peripheral zone. A PSA test, DRE, and if necessary, imaging and biopsy can help distinguish between the two conditions.

Does diet affect prostate cancer risk?

Diet appears to play a moderate role in prostate cancer risk. Diets rich in fruits, vegetables, and healthy fats (such as the Mediterranean diet) have been associated with lower risk in some studies. High intake of red and processed meats, saturated fats, and very high calcium consumption may modestly increase risk. Lycopene from cooked tomatoes, cruciferous vegetables, green tea, and soy have shown potential protective effects, though no single food or nutrient has been proven to prevent prostate cancer definitively.

What is the survival rate for prostate cancer?

The prostate cancer survival rate is among the highest of all cancers. The overall five-year relative survival rate across all stages is approximately 97 percent. For localized and regional disease (which accounts for about 90 percent of diagnoses), the five-year survival rate is nearly 100 percent. For distant (metastatic) disease, the five-year survival rate is approximately 34 percent, though this has been improving with newer therapies. Ten- and fifteen-year survival rates for localized disease remain very high.

Can I still have children after prostate cancer treatment?

Radical prostatectomy removes the prostate and seminal vesicles, making natural conception impossible afterward. Radiation therapy can damage sperm production and quality. Hormone therapy significantly impairs fertility. Men who wish to preserve fertility should discuss sperm banking (cryopreservation) with their doctor before starting any treatment. Sperm banking is simple, non-invasive, and can be arranged quickly before treatment begins.

What questions should I ask my doctor about prostate cancer?

Key questions include: What is my Gleason score, Grade Group, and stage? What are all my treatment options, including active surveillance? What are the expected side effects of each option? How will treatment affect my sexual and urinary function? Should I get a second opinion? Am I a candidate for genetic testing? What is my risk of recurrence? Are there clinical trials I should consider? What lifestyle changes can improve my outcome?

How can I support a partner or loved one with prostate cancer?

Supporting someone with prostate cancer involves being present, listening without judgment, educating yourself about the disease and treatments, attending appointments when welcome, encouraging open communication about fears and concerns (including sexual health), being patient with physical and emotional recovery, helping with practical needs, and taking care of your own emotional well-being. Couples counseling and support groups for partners can be invaluable resources.

Are there any supplements that help with prostate health?

Some supplements have been studied in relation to prostate health, though none are proven to prevent or treat prostate cancer. Selenium and vitamin E were tested in the SELECT trial and showed no benefit (vitamin E actually slightly increased risk). Saw palmetto is commonly used for BPH symptoms but has limited evidence for cancer prevention. Lycopene, green tea extract (EGCG), and vitamin D have shown some promise in preliminary studies but require more research. Always discuss supplements with your healthcare provider, as some may interact with cancer treatments.

References

1. American Cancer Society. (2024). Key statistics for prostate cancer. cancer.org.
2. Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63-89.
3. National Comprehensive Cancer Network (NCCN). (2024). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 4.2024.
4. Mottet, N., et al. (2023). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. European Urology.
5. U.S. Preventive Services Task Force. (2018). Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319(18), 1901-1913.
6. Hamdy, F.C., et al. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547-1558.
7. Mulhall, J.P., et al. (2021). Erectile function rehabilitation in the radical prostatectomy patient. Journal of Sexual Medicine, 18(5), 757-769.
8. Kenfield, S.A., et al. (2011). Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-up Study. Journal of Clinical Oncology, 29(6), 726-732.
9. Thompson, I.M., et al. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3), 215-224.
10. Gandaglia, G., et al. (2021). The role of multiparametric magnetic resonance imaging in prostate cancer diagnosis and staging. European Urology, 80(2), 198-206.
11. Sartor, O., et al. (2021). Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 385(12), 1091-1103.
12. Sanda, M.G., et al. (2018). Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Journal of Urology, 199(3), 683-690.

This article is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, and questions about your individual health. If you are experiencing symptoms or have concerns about prostate cancer, contact your physician promptly.

Looking to support prostate and sexual health naturally? Vitaliboost offers science-backed supplements designed for men's wellness, including formulas that support healthy testosterone levels, prostate comfort, and sexual vitality. Explore our range at vitaliboost.com.